BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Archives
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • September 2024
  • August 2024
  • July 2024
  • May 2024
  • April 2024
  • December 2023
  • October 2023
  • August 2023
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • December 2021
  • November 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Subscribe

Browsing Tag

Biodexa Pharmaceuticals Plc (NASDAQ:BDRX)

2 posts

Biotech NewsBiodexa Pharmaceuticals (BDRX) Launches Phase 3 Trial for eRapa — Can This $2.81M Biotech Transform FAP Treatment?

  • BioTech Health X
  • December 6, 2025
Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for diseases with significant…
0 Shares
0
0
0
0
0
0
0

Biotech NewsBiodexa Pharmaceuticals (BDRX) Launches Phase 3 Trial for eRapa — Can This $2.8M Biotech Deliver a Breakthrough?

  • BioTech Health X
  • December 5, 2025
Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) is a clinical-stage biopharmaceutical company operating within the biotechnology industry and focused on discovering,…
0 Shares
0
0
0
0
0
0
0
Recent Posts
  • Kymera Therapeutics (KYMR) Jumps 10.2% in a Month—Is Wall Street Pricing in a Major 2026 Breakout?
  • Biodexa Pharmaceuticals (BDRX) Launches Phase 3 Trial for eRapa — Can This $2.81M Biotech Transform FAP Treatment?
  • Galectin Therapeutics (GALT) Surges 10.5% After Insider Sells 120,000 Shares
  • Analysts Boost Target to $24 as Ocular Therapeutix (OCUL) Nears Major Catalyst
  • Enveric Biosciences (ENVB) Reports Breakthrough PTSD Results as EB-003 Moves Toward IND in 2026
Recent Comments
  • Novavax Announces Robust First Quarter 2024 Results and Strategic Partnerships • BioTech Health X on Novavax and Sanofi Forge $1.2 Billion Alliance to Boost COVID and Flu Vaccine Efforts
  • Thomas Shentz on Cellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs
  • Tomasz Michałowski on Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
  • Presenters Announced for 2021 William Blair Biotech Conference • BioTech Health X on William Blair Biotech Focus Conference 2021 Panel Schedule
Featured Posts
    • December 6, 2025
    Kymera Therapeutics (KYMR) Jumps 10.2% in a Month—Is Wall Street Pricing in a Major 2026 Breakout?
    • December 6, 2025
    Biodexa Pharmaceuticals (BDRX) Launches Phase 3 Trial for eRapa — Can This $2.81M Biotech Transform FAP Treatment?
    • December 6, 2025
    Galectin Therapeutics (GALT) Surges 10.5% After Insider Sells 120,000 Shares
    • December 6, 2025
    Analysts Boost Target to $24 as Ocular Therapeutix (OCUL) Nears Major Catalyst
    • December 5, 2025
    Enveric Biosciences (ENVB) Reports Breakthrough PTSD Results as EB-003 Moves Toward IND in 2026
Recent Posts
  • Sensei Biotherapeutics (SNSE) Cuts Workforce by 65% as It Prepares for a Potential Sale—Is a Major Buyout Coming?
    • December 5, 2025
  • Viking Therapeutics (VKTX) Surges After 78% of Patients Achieve Normal Glycemic Control in Obesity Trial
    • December 5, 2025
  • West Pharmaceutical Services (WST) Could Outperform as Analysts Project $350.77 Price Target
    • December 2, 2025
Categories
  • BioTech CEO Interviews (9)
  • Biotech Info (5)
  • Biotech News (607)
  • Uncategorized (1)
Author
Hello, I’m
BioTech Health X
Follow
BioTech Health X
Designed & Developed by BioTech Health X
  • About BioTech Health X
  • List of Modern Life Science Technologies
  • Biotechnology Company Directory – List of Major Biotech Companies
  • Contact Us
  • Privacy Policy

Subscribe to
Our Updates

Back to top